JP5247474B2 - Ｃｄ４４の表面発現を証明する細胞の細胞障害性媒介 - Google Patents

Ｃｄ４４の表面発現を証明する細胞の細胞障害性媒介 Download PDF

Info

Publication number
JP5247474B2
JP5247474B2 JP2008556619A JP2008556619A JP5247474B2 JP 5247474 B2 JP5247474 B2 JP 5247474B2 JP 2008556619 A JP2008556619 A JP 2008556619A JP 2008556619 A JP2008556619 A JP 2008556619A JP 5247474 B2 JP5247474 B2 JP 5247474B2
Authority
JP
Japan
Prior art keywords
antibody
cells
antibodies
cancer
microliters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008556619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529497A (ja
JP2009529497A5 (da
Inventor
ヤング、デイヴィッド、エス．、エフ．
フィンドレイ、ヘレン、ピー．
ハーン、スーザン、イー．
セチェット、リサ、エム．
マコンキー、フォルトゥナタ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2009529497A publication Critical patent/JP2009529497A/ja
Publication of JP2009529497A5 publication Critical patent/JP2009529497A5/ja
Application granted granted Critical
Publication of JP5247474B2 publication Critical patent/JP5247474B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70585—CD44

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
JP2008556619A 2006-02-28 2007-02-23 Ｃｄ４４の表面発現を証明する細胞の細胞障害性媒介 Expired - Fee Related JP5247474B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/364,013 US7947496B2 (en) 1999-10-08 2006-02-28 Cytotoxicity mediation of cells evidencing surface expression of CD44
US11/364,013 2006-02-28
PCT/CA2007/000281 WO2007098575A1 (en) 2006-02-28 2007-02-23 Cytotoxicity mediation of cells evidencing surface expression of cd44

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013029374A Division JP2013165710A (ja) 2006-02-28 2013-02-18 Ｃｄ４４の表面発現を証明する細胞の細胞障害性媒介

Publications (3)

Publication Number Publication Date
JP2009529497A JP2009529497A (ja) 2009-08-20
JP2009529497A5 JP2009529497A5 (da) 2012-07-12
JP5247474B2 true JP5247474B2 (ja) 2013-07-24

Family

ID=38458603

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008556619A Expired - Fee Related JP5247474B2 (ja) 2006-02-28 2007-02-23 Ｃｄ４４の表面発現を証明する細胞の細胞障害性媒介
JP2013029374A Pending JP2013165710A (ja) 2006-02-28 2013-02-18 Ｃｄ４４の表面発現を証明する細胞の細胞障害性媒介

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013029374A Pending JP2013165710A (ja) 2006-02-28 2013-02-18 Ｃｄ４４の表面発現を証明する細胞の細胞障害性媒介

Country Status (16)

Country Link
US (3) US7947496B2 (da)
EP (2) EP2508536A1 (da)
JP (2) JP5247474B2 (da)
CN (2) CN101432307B (da)
AU (1) AU2007219656B2 (da)
CA (1) CA2643708A1 (da)
CY (1) CY1115212T1 (da)
DK (1) DK1989233T3 (da)
ES (1) ES2444408T3 (da)
HK (1) HK1120527A1 (da)
NZ (1) NZ570776A (da)
PL (1) PL1989233T3 (da)
PT (1) PT1989233E (da)
SI (1) SI1989233T1 (da)
TW (1) TW200731987A (da)
WO (1) WO2007098575A1 (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013165710A (ja) * 2006-02-28 2013-08-29 F Hoffmann La Roche Ag Ｃｄ４４の表面発現を証明する細胞の細胞障害性媒介

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20090004103A1 (en) * 1999-10-08 2009-01-01 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD44
US20080124327A1 (en) * 1999-10-08 2008-05-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) * 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7419792B2 (en) * 1999-10-08 2008-09-02 Arius Research Inc. Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
CN101663049A (zh) * 2007-03-09 2010-03-03 霍夫曼-拉罗奇有限公司 证明cd44表面表达的细胞的细胞毒性介导
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
CA2793838C (en) 2010-03-19 2019-09-17 H. Lee Moffitt Cancer Center & Research Institute, Inc. Integrin interaction inhibitors for the treatment of cancer
WO2012129335A2 (en) * 2011-03-21 2012-09-27 H. Lee Moffitt Cancer Center And Research Institute, Inc Hyd1 peptides for relapsed cancer
WO2013035824A1 (ja) 2011-09-07 2013-03-14 ファーマロジカルズ・リサーチ プライベート リミテッド 癌幹細胞の分離
WO2015048477A1 (en) 2013-09-27 2015-04-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cyclic peptide conjugates and methods of use
CN109402064B (zh) * 2018-11-05 2021-05-14 湖南省肿瘤医院 杂交瘤细胞株及其产生的单克隆抗体和应用
CN112569351B (zh) * 2020-12-16 2021-10-15 南通大学 Cd44抗体在制备治疗帕金森疾病的药物中的应用
CN114250200A (zh) * 2021-12-23 2022-03-29 蚌埠医学院 一种非小细胞肺癌脑转移和脊髓转移的动物模型构建方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US486158A (en) 1892-11-15 John cook
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
EP0266032A1 (en) 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
NZ222509A (en) * 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US4861581A (en) * 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5171665A (en) * 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5980896A (en) * 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
DE4014510A1 (de) * 1990-05-07 1991-11-14 Kernforschungsz Karlsruhe Variante cd44-oberflaechenproteine, diese kodierende c-dna-sequenzen, antikoerper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69229254T2 (de) * 1991-10-30 1999-09-23 Idemitsu Kosan Co Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
IL105008A0 (en) * 1992-03-13 1993-07-08 Yeda Res & Dev Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis
CA2149635A1 (en) 1992-11-20 1994-06-09 David Tarin Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors
US5879898A (en) * 1992-11-20 1999-03-09 Isis Innovation Limited Antibodies specific for peptide corresponding to CD44 exon 6, and use of these antibodies for diagnosis of tumors
ATE244888T1 (de) * 1993-02-05 2003-07-15 Epigen Inc Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy
US5693322A (en) * 1993-03-11 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Enhanced intercellular interaction by associational antibody molecules
EP0703989B1 (en) 1993-06-18 1997-11-05 Oy Biotie Therapies COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6
WO1995020401A1 (en) 1994-01-31 1995-08-03 Trustees Of Boston University Polyclonal antibody libraries
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти
EP1018518A2 (en) * 1994-06-24 2000-07-12 Vladimir P. Torchilin Use of autoantibodies for tumor therapy and prophylaxis
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
WO1998006839A1 (en) * 1996-07-15 1998-02-19 Human Genome Sciences, Inc. Cd44-like protein
ES2176574T3 (es) * 1996-09-03 2002-12-01 Gsf Forschungszentrum Umwelt Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral.
DE19653607A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen
DE19708713C2 (de) * 1997-03-04 2002-11-28 Boehringer Ingelheim Int Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen
US5816468A (en) * 1997-06-24 1998-10-06 Testo Industries Corp. No-idle-striking structure for nailing machines
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6180357B1 (en) * 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7252821B2 (en) 1999-10-08 2007-08-07 Arius Research Inc. Cancerous disease modifying antibodies
US7189397B2 (en) 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6657048B2 (en) * 1999-10-08 2003-12-02 Arius Research, Inc. Individualized anti-cancer antibodies
US20040001789A1 (en) * 1999-10-08 2004-01-01 Young David S. F. Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof
CZ20032787A3 (en) 2001-04-03 2004-03-17 Merck Patent Gmbh Renal cell carcinoma tumor markers
YU91403A (sh) 2001-05-18 2006-05-25 Boehringer Ingelheim International Gmbh. Antitela specifična za cd44v6
US20030103985A1 (en) * 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
CA2471206A1 (en) 2001-12-21 2003-07-10 Arius Research, Inc. Individualized anti-cancer antibodies
US7399835B2 (en) * 2004-02-26 2008-07-15 Arius Research Inc. Cancerous disease modifying antibodies
US7319674B2 (en) 2003-07-24 2008-01-15 Cisco Technology, Inc. System and method for exchanging awareness information in a network environment
US7348413B2 (en) * 2004-02-26 2008-03-25 Arius Research Inc. Cancerous disease modifying antibodies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013165710A (ja) * 2006-02-28 2013-08-29 F Hoffmann La Roche Ag Ｃｄ４４の表面発現を証明する細胞の細胞障害性媒介

Also Published As

Publication number Publication date
PT1989233E (pt) 2014-02-11
CN101432307A (zh) 2009-05-13
AU2007219656A1 (en) 2007-09-07
AU2007219656B2 (en) 2013-02-07
EP1989233B1 (en) 2013-11-06
US20060216233A1 (en) 2006-09-28
CN103197067A (zh) 2013-07-10
TW200731987A (en) 2007-09-01
US20120107233A1 (en) 2012-05-03
CY1115212T1 (el) 2017-01-04
EP1989233A1 (en) 2008-11-12
JP2013165710A (ja) 2013-08-29
WO2007098575A1 (en) 2007-09-07
DK1989233T3 (da) 2014-01-13
ES2444408T3 (es) 2014-02-24
CA2643708A1 (en) 2007-09-07
CN101432307B (zh) 2013-06-12
US7947496B2 (en) 2011-05-24
US20080274049A1 (en) 2008-11-06
HK1120527A1 (en) 2009-04-03
EP2508536A1 (en) 2012-10-10
JP2009529497A (ja) 2009-08-20
SI1989233T1 (sl) 2014-02-28
PL1989233T3 (pl) 2014-04-30
NZ570776A (en) 2011-03-31
EP1989233A4 (en) 2010-05-05
US8017117B2 (en) 2011-09-13

Similar Documents

Publication Publication Date Title
JP5247474B2 (ja) Ｃｄ４４の表面発現を証明する細胞の細胞障害性媒介
CA2687583C (en) Chimeric and humanized anti-cd44 antibodies that mediate cancer cell cytotoxicity
US8388961B2 (en) Cytotoxicity mediation of cells evidencing surface expression of CD44
JP2009531293A (ja) Ｃｄ５９表面発現の証拠となる、細胞における細胞毒性の媒介
JP2009507771A (ja) 癌性疾患修飾抗体
KR20090059106A (ko) 암 질환 변경 항체
JP2010516629A (ja) 癌性疾患修飾抗体
US20080131429A1 (en) Cytotoxicity mediation of cells evidencing surface expression of CD44
JP2009502978A (ja) 癌性疾患修飾抗体
JP2009502981A (ja) 癌性疾患修飾抗体
JP2009507772A (ja) 癌性疾患修飾抗体
JP2009502979A (ja) 癌性疾患修飾抗体
AU2013202753A1 (en) Chimeric and humanized anti-CD44 antibodies that mediate cancer cell cytotoxicity
JP2011528010A (ja) 癌性疾患修飾抗体
US20070189964A1 (en) Cytotoxicity mediation of cells evidencing surface expression of CD44
JP2009502980A (ja) 癌性疾患修飾抗体

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120418

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130327

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130409

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160419

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees